REVEAL Lite 2 risk calculator a simplified model to assess mortality risk in PAH

February 23, 2021

3 min read

Source/Disclosures

Disclosures: The study was funded by Janssen Pharmaceuticals, the sponsor of the REVEAL Registry. Benza reports he received grants from the American Heart Association, Bayer, the National Heart, Lung, and Blood Institute, and United Therapeutics; and received research support and served as a paid consultant for Janssen Please see the study for all other authors’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Use of an abridged version of the REVEAL 2.0 risk calculator, REVEAL Lite 2, provided a simplified method of mortality risk assessment for patients with pulmonary arterial hypertension, researchers reported in Chest.

“REVEAL Lite 2 was developed to provide clinicians with a simplified risk calculation method that can be routinely implemented in clinical practice, where data for patients may lack and be time-constrained,” Raymond L…

Want to know more click here go to source.

From Healio - February 24, 2021